An initial VSV-IFNβ variant drove tumor escape via a predictable CSDE1 (Cold Shock Domain-containing E1) mutation (CSDE1P5S) that enabled tumors to evade oncolytic virotherapy. This evidence concerns the gene CSDE1 and neoplasm.